Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the lining of the large intestine (colon) and rectum. It is characterized by inflammation, ulcers, and bleeding in the colon and rectum, which can lead to symptoms such as abdominal pain, diarrhea, and rectal bleeding. The exact cause of ulcerative colitis is unknown, but it is thought to be related to an abnormal immune response in which the body’s immune system attacks the cells of the digestive tract. The condition may also be influenced by genetic and environmental factors. There are several treatment options available to manage the symptoms and complications of ulcerative colitis, including medications to reduce inflammation and suppress the immune system, dietary changes, and surgery to remove the affected portion of the colon or rectum in severe cases. 根据最新估计, the ulcerative colitis in China market size is expected to increase from USD 857.8 百万 2022 兑美元 2,061.0 百万 2029, 复合年增长率为 13.09% 在评估期内.

这份行业报告提供了中国市场的市场预测, 其次是类型的详细分析, and product. The China market data on ulcerative colitis can be segmented by type: 轻度溃疡性结肠炎, 中度至重度溃疡性结肠炎. Ulcerative colitis market is further segmented by product: 英夫利昔单抗, 美沙拉嗪, 柳氮磺吡啶 (SS), 其他的.

作为 2022, the major players in the China ulcerative colitis market were Losan Pharma GmbH, Ferring Holding SA, Guangdong Qiangji Pharmaceutical Co. 有限公司, Janssen Pharmaceuticals Inc., Shanghai Sine Tianping Pharmaceutical Co. 有限公司.

以数据为中心的报告重点关注市场趋势, 各细分市场的现状和前景. 全面覆盖不同细分市场, 该报告对于现有参与者来说是宝贵的资产, 新进入者和未来投资者.

为什么购买这份报告?
▹ Get a detailed picture of the China Ulcerative Colitis Market
▹ Identify segments/areas to invest in over the forecast period in the China Ulcerative Colitis Market
▹ 了解竞争环境, 市场的领先参与者
▹ Excel 格式的市场预估，方便跨场景分析.
▹ 三个月的策略咨询和研究支持.
▹ 为单用户许可证提供打印验证.